Undén Johan, Bellner Johan, Eneroth Magnus, Alling Christer, Ingebrigtsen Tor, Romner Bertil
Department of Neurosurgery, Lund University Hospital, Lund, Sweden.
J Trauma. 2005 Jan;58(1):59-61. doi: 10.1097/01.ta.0000130613.35877.75.
S100B, a protein abundant in astroglial cells within the central nervous system, has been shown to increase in cerebrospinal fluid and serum after various neurologic diseases. However, the cerebral specificity of S100B has been questioned. This study aims to show serum S100B levels after uncomplicated bone fractures in patients without current or prior neurologic diseases.
Blood for sampling was drawn from patients seeking care at the emergency department presenting with various uncomplicated orthopedic fractures no older than 24 hours and having no previous or suspected neurologic disorder or head injury.
Fifty-five consecutive patients with acute fractures were included in the study. Serum S100B levels were raised above 0.15 microg/L in 16 of 55 (29%) patients (range, 0.02-0.51 microg/L; mean, 0.13 +/- 0.11 microg/L).
S100B levels were raised in 29% of patients with acute fractures without apparent cerebral injury, which suggests an extracerebral source of S100B. This information should be taken into account when interpreting S100B levels when dealing with brain damage.
S100B是一种在中枢神经系统星形胶质细胞中大量存在的蛋白质,已证实在各种神经系统疾病后,其在脑脊液和血清中的水平会升高。然而,S100B的脑特异性受到了质疑。本研究旨在显示无当前或既往神经系统疾病的患者在发生单纯性骨折后的血清S100B水平。
从急诊科就诊的患者中采集血样,这些患者患有各种不复杂的骨科骨折,骨折时间不超过24小时,且无既往或疑似神经系统疾病或头部损伤。
55例急性骨折患者连续纳入研究。55例患者中有16例(29%)血清S100B水平升高至0.15μg/L以上(范围为0.02 - 0.51μg/L;平均值为0.13±0.11μg/L)。
29%无明显脑损伤的急性骨折患者血清S100B水平升高,这表明S100B存在脑外来源。在处理脑损伤时解释S100B水平时应考虑这一信息。